SGLT2 inhibitors primarily reduce heart failure hospitalisation through hemodynamic effects [35], while pioglitazone's cardiovascular benefits appear mediated through impacts on coronary atherosclerosis progression as demonstrated in the PERISCOPE trial [17] and suggested in the PROactive study [36]. Here, SLC5A2 is linked to heart failure.